Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Potential Treatment for Overactive Bladder Syndrome
July 09 2024 - 8:00AM
Business Wire
Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue
Pharma L.P. (“Purdue”), achieved last patient last visit in its
Phase 1b study of the investigational drug sunobinop as a potential
treatment for overactive bladder syndrome (OAB)*.
Sunobinop is an investigational, novel and potential
first-in-class oral compound discovered by Imbrium Therapeutics and
that is currently in clinical development. Sunobinop is designed to
bind to and activate the nociceptin/orphanin-FQ peptide receptor
(NOP), a protein that is widely expressed in the central and
peripheral nervous system1 and involved in a range of biological
functions, including bladder function.2,3
Fifty-one female patients suffering from OAB were enrolled in
this multicenter, randomized, double-blind, placebo-controlled
crossover study. The study was designed to test the effects of
sunobinop at bedtime on key disease symptoms, such as urinary
urgency, frequency, incontinence, and nocturia in subjects with OAB
compared to placebo. OAB is a life-long urologic disorder that
reduces patients’ quality of life. The condition affects 14% of men
and women in the U.S.4
"Millions of patients with overactive bladder are in need of
additional treatment options for the disruptive, distressing
symptoms. This study will help us learn more about sunobinop’s
potential to be a new treatment option,” said Dr. Julie Ducharme,
Vice President and Chief Scientific Officer. “We look forward to
reviewing and analyzing the results later this year.”
“We are pleased to achieve last patient last visit in the
sunobinop Phase 1b study,” said Craig Landau, MD, President and CEO
of Purdue. “Our continued progress in this work demonstrates our
ongoing commitment to innovation through research and
development.”
In addition to OAB, Imbrium is also evaluating sunobinop as a
potential treatment for interstitial cystitis/bladder pain syndrome
(IC/BPS) and separately for alcohol use disorder.
*This release discusses investigational uses of an agent in
development and is not intended to convey conclusions about
efficacy or safety. There is no guarantee that sunobinop will
successfully complete development or gain FDA approval.
About Imbrium Therapeutics L.P. Imbrium is a
clinical-stage biopharmaceutical company dedicated to advancing
medical science through the development of important new
therapeutics. We are pursuing treatments for genitourinary
disorders, disorders of the central nervous system, oncology
chemotherapeutics, and non-opioid approaches to the management of
pain. As a subsidiary of Purdue Pharma L.P., Imbrium strives to
develop new medicines that serve the unmet needs of patients,
physicians, and health systems worldwide. We have built a robust
and diversified pipeline of investigational drug candidates, and we
seek to actively collaborate with industry and academic partners to
identify and advance future impactful medicines. For more
information, please visit www.imbriumthera.com.
References 1. Zaveri, N. The nociceptin opioid receptor
(NOP) as a therapeutic target: Progress in translation from
preclinical research to clinical utility. J Med Chem. 2016; 59(15):
7011-7028.
2. Lambert, D. The nociception/orphanin FQ receptor: a target
with broad therapeutic potential. Nat. Rev. 2008
Aug;7(8):694-710.
3. Lazzeri, M., Calò, G., Spinelli, M., et al. Daily
intravesical instillation of 1 mg nociceptin/orphanin FQ for the
control of neurogenic detrusor overactivity: a multicenter, placebo
controlled, randomized exploratory study. J Urol. 2006
Nov;176(5):2098-102.
4. Reynolds, W., Fowke, J., & Dmochowski, R. The burden of
overactive bladder on US public health. Current Bladder Dysfunct
Rep. 2016 Mar;11(1):8-13.
MR-08567
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709392458/en/
Media: news@pharma.com